Extensive liver resection with preoperative regional chemotherapy for colorectal metastases in patients with high risk of blood loss

Abstract

Objective: to study influence of regional chemo- and biotherapy on intraoperative blood loss. Materials and methods: An analysis of 122 cases of extensive liver resection accompanied with regional chemotherapy in colorectal metastases patients has been performed. 69 (57%) of them had bilobar lesions, 58 (48%) - had multiple metastases, 27 (22%) - had been resected for extrahepatic metastases. Results: bevacizumab inclusion in preoperative regional chemotherapy did not lead to increase of intraoperative blood loss. Conclusion: Median intraoperative blood loss was 1200 ml in both groups. Up to 6 courses of preoperative antitumor therapy, regardless of route of drug introduction did not increase blood loss. Intraoperative blood loss increases from standard to extended liver resection. Resection of contralateral lobe metastases did not lead to statistically significant increase in blood loss as compared with standard operation.

Keywords

colorectal cancer metastases / preoperative regional chemotherapy / blood loss

References

[1] Журавлев В.А. Радикальные операции у «неоперабельных» больных с очаговыми поражениями печени. Киров: Вятка; 2000.

[2] Патютко Ю.И. Хирургическое лечение злокачественных опухолей печени. М.: Медицина; 2005.

[3] Патютко Ю.И., Пылев А.Л., Сагайдак И.В., Котельников А.Г. и др. Современные подходы к лечению метастазов колоректального рака в печению. Вестник хирургической гастроэнтерологии. 2008; 4: 14-28.

[4] Вишневский В.А., Назаренко Н.А., Икрамов Р.З., Рузавин B.C., Козырин И.А. Обширные резекции печени при высоком риске массивной кровопотери. Альманах Института хирургии имени А.В. Вишневского. 2008; 3(3): 18-22.

[5] Adam R., Laurel A., Azoulay D. et al. Twostagehepatectomy: A planned strategy to treat irresectable liver tumors. Ann. Surg. 2000; 232: 777-85.

[6] Adam R., Pascal G., Castaing D. et al. Tumor progression while on chemotherapy. A contraindication to liver resection for multiple colorectal metastases? Ann. Surg. 2004; 240: 1052-64.

[7] Azoulay D., Andreani P., Maggi U. et al. Combined liver resection and reconstruction of the supra-renal vena cava: The Paul Brousse experience. Ann. Surg. 2006; 244: 80-8.

[8] Кетеnу M.M., Adak S., Gray B. et al. Combined-modality treatment for resectable metastatic colorectal carcinoma to the liver: surgical resection of hepatic metastases in combination with continuous infusion of chemotherapy-an intergroup study. J. Clin. Oncol. 2002; 20(6):1499-505.

[9] Abdalla E.K., Adam R. et al. Improving respectability of hepatic colorectal metastases: Expert consensus statement. Ann. Surg. Oncol. 2006; 13(10): 1271-80.

[10] Clavien P.-A., Petrowsky H. et al. Strategius for safer liver surgeri and partial liver transplantation. N. Engl. J. Med. 2007; 356(15): 1545-59.

[11] Tournigand C., Andre T., Achille E. et al. FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: A randomized GERCOR Study. J. Clin. Oncol. 2004; 22: 229-37.

[12] Nordlinger B., Sorbye H., Debois M. et al. Feasibility and risks of preoperative chemotherapy with FOLFOX 4 and surgery for resectable colorectal liver metastases: Interim results of the EORTC Intergroup randomized phase III study. J. Clin. Oncol. 2005; 23 (Suppl.): 253.

[13] Saltz L.B., Cox J.V., Blanke C. et al. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. N. Engl. J. Med. 2000; 343(13): 905-14.

[14] Gruenberger T., Tamandl D., Puhalla H. et al. Bevacizumab plus XELOX as neoadjuvant therapy for patients with potentially curable metastatic colorectal cancer. In: Meeting Proceedings 43rd ASCO. 2007: Abstr. 4064.

[15] D’Angelica M., Komprat P., Gonen M. et al. Lack of evidence for increased operative morbidity after hepatectomy with perioperative use of bevacizumab: a matched case-control study. Ann. Surg. Oncol. 2007; 14(2): 759-65.

RIGHTS & PERMISSIONS

Eco-Vector